Dong Sung Pharm: The Fate of a 68-Year-Old Pharmaceutical Company Rests in the Hands of Creditors and Shareholders

Dong Sung Pharm, with its 68-year history, is currently in turmoil during its rehabilitation process due to an intense conflict between its new owner, Brand Refactoring, and the current administrator, former CEO Na Wonkyun.

The dispute between the two parties has escalated beyond a simple management rights struggle, expanding into a complex conflict involving legal responsibility, the legitimacy of the rehabilitation process, potential investor losses and avoidance of responsibility, and even the future direction of Korea's corporate rehabilitation system.

Brand Refactoring recently became the largest shareholder of Dong Sung Pharm and has announced its intention to normalize the company by injecting approximately 15 billion KRW. In contrast, the current administrator, CEO Na Wonkyun, is pursuing an external merger and acquisition (M&A) before the rehabilitation approval stage. Effectively, both sides are presenting different rehabilitation scenarios and are in direct confrontation.

The Brand Refactoring side strongly opposes Na's pre-approval M&A attempt, claiming it is "a means to deprive existing shareholders of their rights and defend management control." They argue that Na applied for rehabilitation proceedings without warning, despite knowing about the change in the largest shareholder, and that he brought up the M&A option only after Brand Refactoring secured control.

The conflict has already escalated into a legal battle. Brand Refactoring has filed criminal complaints against former largest shareholder and ex-CEO Lee Yanggu and current administrator Na for fraud and breach of trust under the Act on the Aggravated Punishment of Specific Economic Crimes. They claim that these illegal acts triggered the rehabilitation process and prevented them from exercising their legitimate rights as the largest shareholder.

Furthermore, Brand Refactoring has reported a damage compensation claim, stating that if shareholder losses such as capital reduction or stock cancellation occur due to the M&A, legal responsibility lies with former CEO Na and the Dong Sung Pharm corporation. If this claim is recognized, it is analyzed that any third-party acquirer would also bear this legal risk, making it difficult for new acquirers to approach.

Within Dong Sung Pharm, the struggle for management rights has also intensified. Recently, the board of directors replaced CEO Na Wonkyun with Yoo Youngil, an executive from Brand Refactoring. Brand Refactoring has called this "a signal for restructuring the governance structure" and is demanding the immediate dismissal of administrator Na Wonkyun.

Their claims are also supported by the court-appointed investigator's report. The report is said to point out not only the management responsibility of former CEO Lee Yanggu but also failures in internal control and poor fund management under Na Wonkyun's regime. Based on this, Brand Refactoring has argued that "executives responsible for the company's insolvency under the Debtor Rehabilitation and Bankruptcy Act are not qualified to serve as administrators," presenting a legal basis for dismissal.

Ultimately, the direction of Dong Sung Pharm's rehabilitation depends on the choice of creditors and shareholders. If the M&A plan pushed by former CEO Na is approved, a large-scale capital reduction and stock cancellation will be inevitable, effectively erasing existing shareholders' stakes.

On the other hand, Brand Refactoring's proposed autonomous normalization plan aims to inject more than 15 billion KRW, secure a higher repayment rate for creditors, maintain shareholder value, and successfully exit the rehabilitation process.

For creditors, the key issue is whether the uncertain recovery prospect through M&A or the stable repayment based on capital injection is the more realistic option. At the stakeholders' meeting to be held at the Seoul Bar Association Hall on October 22, the choices made by creditors and shareholders will not only determine the fate of the company but are also expected to set an important precedent for the future operation of the corporate rehabilitation system.

The Dong Sung Pharm case is a clash not of financial issues, but of governance structure and legal legitimacy. A Brand Refactoring official stated, "There is a fundamental question of whether it is legally legitimate for management to apply for rehabilitation and pursue pre-approval M&A during the process, thereby neutralizing shareholders' rights, even when a largest shareholder exists." He added, "The outcome of this decision, whether it leads to Dong Sung Pharm's survival and rehabilitation or impacts the trust in Korea's capital market, now rests in the hands of the creditors."

This content was produced with the assistance of AI translation services.